SB 253 · 2025 · Senate · Health and Human Services Committee
Protect 340B drug program access
AI-generatedrelative to participation in the federal 340B Drug Pricing Program.
Prohibits drug manufacturers from denying or restricting a covered entity's acquisition of a 340B program drug and from requiring certain claims or utilization data unless required by federal law, making violations subject to the consumer protection act.AI-generated
Status
Killed in the Senate — Inexpedient to Legislate · March 6, 2025- ✓Introduced
- ✕Senate
- House
- Governor
- Law
Analysis
This bill prohibits a drug manufacturer from denying or restricting acquisition or delivery of a 340B covered drug by a covered entity unless receipt of the drug is prohibited by federal law. The bill also prohibits a drug manufacturer from requiring certain claims or utilization data from the 340B covered entity unless required by federal law. The bill makes such actions a violation of the consumer protection act.
From the bill's official ANALYSIS section.
Official record
gc.nh.gov · the authoritative source
Sponsors
- Sen. Bill GannonRChair· Judiciary
Public testimony
No one submitted online testimony on this bill. See the record
Hearings
- 2025-02-199:00 amSenate Health and Human ServicesSH 100Public hearing
Legislative history
- Jan 9, 2025SenIntroduced 01/09/2025 and Referred to Health and Human Services; SJ 3
- Feb 19, 2025SenHearing: 02/19/2025, Room 100, SH, 09:45 am; SC 10
- Mar 6, 2025Sen: Inexpedient to Legislate, 03/06/2025, Vote 3-2; SC 11
- Mar 6, 2025SenInexpedient to Legislate, MA, VV === BILL KILLED ===; 03/06/2025; SJ 6
Coverage
No reporting linked yet.
Documents (PDF)
Bill text & amendments link direct to gc.nh.gov; committee reports stream from the state record.